Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Inclusion Criteria: * Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy Exclusion Criteria: * LDL-C levels \> 250 mg/dL (6.48 mmol/L) * Triglycerides levels \> 350mg/dL (3.95 mmol/L) * Conditions / situations such as: * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels * Active liver disease * High estimated risk of Coronary Heart Disease * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive * Pregnant or breast-feeding women, * Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product * Hypersensitivity to any component of atorvastatin * Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine, erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing the risk of myopathy with atorvastatin The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.